Quick Answer
DEXCOM INC reported R&D Expense of $599.10 million for fiscal year 2025.
DEXCOM INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $599.10M | +8.5% |
| 2024 | $552.40M | +9.2% |
| 2023 | $505.80M | +4.5% |
| 2022 | $484.20M | -6.4% |
| 2021 | $517.10M | +43.7% |
| 2020 | $359.90M | +31.6% |
| 2019 | $273.50M | +37.0% |
| 2018 | $199.70M | +7.7% |
| 2017 | $185.40M | +18.8% |
| 2016 | $156.10M | +13.5% |
| 2015 | $137.50M | +98.1% |
| 2014 | $69.40M | +54.9% |
| 2013 | $44.80M | +17.0% |
| 2012 | $38.30M | +29.4% |
| 2011 | $29.60M | +27.6% |
| 2010 | $23.20M | +62.3% |
| 2009 | $14.29M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $157.50M | +16.3% | +6.3% |
| June 30, 2025 | $148.20M | +9.0% | +2.1% |
| March 31, 2025 | $145.20M | +2.6% | +7.2% |
| September 30, 2024 | $135.40M | +3.0% | -0.4% |
| June 30, 2024 | $136.00M | +14.0% | -3.9% |
| March 31, 2024 | $141.50M | +18.9% | +7.7% |
| September 30, 2023 | $131.40M | +19.1% | +10.1% |
| June 30, 2023 | $119.30M | -2.0% | +0.3% |
- DEXCOM INC showed an increase of +8.5% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, DEXCOM INC’s r&d expense has grown by 4091.3% (from $14.29 million to $599.10 million).
- The most recent figure is from DEXCOM INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: